pembrolizumab,toripalimab,nivolumab,ipilimumab,Atezolizumab,durvalumab,carboplatin,pemetrexed,paclitaxel,cisplatin,gemcitabine
merck,Roche,BMS,Coherus,Junshi Biosciences,Astrazeneca
['keynote,671', 'keynote-671']
great discussion by dr. on keynote-671 putting the findings into context. many factors (e.g. genomic features, clinical and pathologic characteristics) to consider when choosing the best io approch for patients. multi-d discussion is essential.
#asco23 
Thoracic Medical Oncologist at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM